Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 9/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.53 |
| ▸ | LIPE | Q05469 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656078 | 0.90 | GCK (0.56) | GCKKCNH2LIPEHRH3GRM5 | |
| SCHEMBL1427115 | 0.89 | GCK (0.54) | GCKKCNH2LIPEHRH3MEN1 | |
| SCHEMBL1379103 | 0.84 | GCK (0.76) | GCKKCNH2 | |
| SCHEMBL1427058 | 0.84 | GCK (0.58) | GCKKCNH2LIPEHRH3MEN1 | |
| SCHEMBL2655987 | 0.83 | GCK (0.53) | GCKKCNH2LIPEHRH3MEN1 | |
| SCHEMBL1427136 | 0.83 | GCK (0.74) | GCKKCNH2 | |
| SCHEMBL2654354 | 0.82 | GCK (0.60) | GCKKCNH2 | |
| SCHEMBL1427062 | 0.82 | GCK (0.62) | GCKKCNH2LIPEHRH3 | |
| SCHEMBL1652809 | 0.82 | GCK (0.62) | GCKKCNH2LIPEHRH3 | |
| SCHEMBL2667106 | 0.81 | GCK (0.49) | GCKKCNH2LIPEHRH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |